

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

## TERMINAL DISCLAIMER

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are

statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. I.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Idenix Pharmaceuticals, Inc.**

Date: March 30, 2007

By:



Name: Jean-Pierre Sammache

Position: Chief Executive Officer

**Universita Degli Studi di Cagliari**

Date: \_\_\_\_\_

By: \_\_\_\_\_

Name: \_\_\_\_\_

Position: \_\_\_\_\_

**Centre National de la Recherche Scientifique**

Date: \_\_\_\_\_

By: \_\_\_\_\_

Name: \_\_\_\_\_

Position: \_\_\_\_\_

**L' Université Montpellier II**

Date: \_\_\_\_\_

By: \_\_\_\_\_

Name: \_\_\_\_\_

Position: \_\_\_\_\_

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:)	11874-016-999 417451-999016 IDX 1017

## TERMINAL DISCLAIMER

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Università Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Università Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are

statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Idenix Pharmaceuticals, Inc.**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

Date: 23-03-2009 By: Bellantufo  
  
Name: **IL RETTORE**  
Position: *(Pasquale Mistretta)*

**Centre National de la Recherche Scientifique**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

**L' Université Montpellier II**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

## TERMINAL DISCLAIMER

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are

statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Idenix Pharmaceuticals, Inc.**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

**Universita Degli Studi di Cagliari**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:


Position:

**Centre National de la Recherche Scientifique**

Date: 30 MARS 2009 By: \_\_\_\_\_ Directeur de la Politique Industrielle

Name:

Position:

  
Marc J. LEDOUX

**L' Université Montpellier II**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016 IDX 1017

## TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219, 6,914,054 and 7,105,493 ("the reference patents"). The owners hereby waive the right to separately enforce the reference patents and any patent granted on the above-identified application. The owners hereby agree that the reference patents and any patent granted on the above-identified application shall be enforceable only for and during such period that the reference patents and any patent granted on the above-identified application are not separately enforced.

Ownership of the above-identified application in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

Ownership of the reference patents in Idenix Pharmaceuticals, Inc. and Universita Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; August 19, 2002 at reel 013193 frame 0841; September 13, 2001 at reel 012162 frame 0294; and February 25, 2003 at reel 013786 frame 0068.

The owners further agree that the waiver, and this agreement, run with any patent granted on the above-identified application and are binding upon the owners, their successors, or assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory terms of the reference patents in the event that one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are

statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the waiver and this agreement as stated above.

The undersigned hereby confirm they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Idenix Pharmaceuticals, Inc.**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

**Universita Degli Studi di Cagliari**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

**Centre National de la Recherche Scientifique**

Date: \_\_\_\_\_ By: \_\_\_\_\_

Name:

Position:

**L' Université Montpellier II**

Date: 12/03/2003 By: \_\_\_\_\_

Name: Mme Danièle HÉRIN

Position: Habitante

- 2 -



## PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "*Assignment*"), effective as of March 4, 2009 (the "*Effective Date*"), is made by and among Idenix Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA ("*Idenix USA*"), Idenix SARL, a [corporation] organized under the laws of France ("*Idenix France*"), Idenix (Cayman) Limited, a company organized under the laws of the Cayman Islands ("*Idenix Cayman*"), the Università degli studi di Cagliari, a university organized under the laws of Italy ("*University of Cagliari*"), the Centre National Del La Recherche Scientifique, a [corporation] organized under the laws of France ("*CNRS*"), and L'Université Montpellier II, a [public institution] organized under the laws of France ("*UM II*"). (Idenix USA, Idenix France, Idenix Cayman, University of Cagliari, CNRS and UM II also may be referred to herein individually as a "party" and collectively as the "parties.")

### *RECITALS*

A. Idenix France, on behalf of itself and Idenix USA, and CNRS and UM II are parties to that certain Restated and Amended Cooperative Joint Research Agreement dated as of May 7, 2003 (the "*French Joint Research Agreement*"), pursuant to which each of the parties thereto agreed to jointly own all "Results" (as defined therein) and patents covering such Results.

B. Idenix France, through its predecessor Novirio SARL, and the University of Cagliari are parties to that certain Co-Operative Antiviral Research Activity Agreement dated January 4, 1999, as amended (the "*Italian Joint Research Agreement*"), pursuant to which each of them have agreed to jointly own all results obtained from the activities taken thereunder and patents covering such results.

C. Idenix France, through its predecessor Novirio SARL, and Idenix Cayman, through its contributor Novirio Pharmaceuticals Limited, a corporation formerly organized under the laws of the Cayman Islands, are parties to that certain Research and Development Agreement dated as of August 24, 1998 pursuant to which Idenix Cayman owns all intellectual property rights developed pursuant to "Projects" (as defined therein), except certain of such rights owned by Idenix USA.

D. The inventors of the United States and foreign patents and patent applications listed on Attachment A assigned their individual rights, titles and interests to their respective employers before the Effective Date.

E. The parties desire that each of Idenix USA, University of Cagliari, CNRS and UM II (collectively, the "*Joint Assignees*") each jointly own an equal, undivided right, title and interest in the Jointly Owned Patents (as defined below), subject to the rights and obligations of each Joint Assignee with respect thereto set forth in the French Joint Research Agreement or the Italian Joint Research Agreement, as applicable, through partial assignments by the respective owners as of the Effective Date as necessary to accurately document and record such agreement.

### *AGREEMENT*

NOW, THEREFORE, for good and valuable consideration (including the premises and covenants set forth in the Italian Joint Research Agreement and the French Joint Research Agreement), the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Each of the parties (each an "*Assignor*") hereby irrevocably assigns, transfers and sets over to the Joint Assignees all or such portion of such Assignor's right, title and interest in and to the patents and patent applications listed on Attachment A (if any), together with any foreign counterparts or equivalents thereto, existing now or in the future and including, but not limited to, patents of utility, improvement or addition, utility model and appearance and industrial design patents and inventors certificates, as well as divisionals, reissues, continuations (in whole or in part), renewals and extensions of any of the foregoing and any patents that may issue from any of the foregoing or any reissues or reexaminations thereof, and including the inventions described or claimed in the foregoing (all of the foregoing, collectively, "*Jointly Owned Patents*"), for each Joint Assignee's use and enjoyment, and for the use and enjoyment of their respective successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment had not been made, in each case such that all of the Joint Assignees hereby jointly own an equal, undivided right, title and interest to all of the *Jointly Owned Patents*, subject to the terms and conditions of the French Joint Research Agreement and Italian Joint Research Agreement, as applicable.

Each Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other similar government authority to record each Joint Assignee as a joint owner of the *Jointly Owned Patents* and issue any and all patents issued thereon to the Joint Assignees jointly, as assignees collectively of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of the Joint Assignees jointly and their respective successors, assigns or other legal representatives.

Assignors shall provide the Joint Assignees and their respective successors, assigns or other legal representatives, reasonable cooperation and assistance, including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation, as may be reasonably required in the implementation, recordation or perfection of this Assignment. Each of the parties hereby irrevocably appoints Idenix USA and its successors, assigns and other legal representatives as the true and lawful attorney-in-fact on Assignor's and Joint Assignee's behalf and in Assignor's and/or Joint Assignee's name, place and stead, to execute any further documents or instruments and do any and all further acts that may be deemed appropriate by Idenix USA and its successors, assigns and other legal representatives to effect the assignments to the Joint Assignees and their respective successors, assigns and other legal representatives, of the rights, titles and interests made hereby, and to enable such assignments to be recorded and/or perfected in the United States and all foreign countries, and to maintain, issue or extend any *Jointly Owned Patents*.

Each party is solely responsible for its costs and expenses associated with the execution and delivery of this Assignment. Each Joint Assignee shall be responsible for 25% of all of the out of pocket costs and expenses actually incurred by Idenix USA in connection with the recording or other perfection of this Assignment within the United States and all foreign

countries, including, but not limited to, any recording fees, taxes or other charges payable to any governmental authority or local attorney/agent in connection therewith.

This Assignment may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. This Assignment is governed by the laws of the State of Delaware.


*<signature pages follow>*

IN WITNESS WHEREOF, each of the parties have executed and delivered this Assignment to effective as of the Effective Date.

**Idenix Pharmaceuticals, Inc.**

By:   
Name: Jean-Pierre Sonneville  
Title: Chief Executive Officer

**Idenix SARL**

By: 

Name: Jean-Pierre Saurin, d'Assie

Title: Directeur

**Idenix (Cayman) Limited**

By: 

Name: Jean-Pierre Sonnenberg

Title: Director

Università degli studi di Cagliari

By: \_\_\_\_\_  
Name: PASQUALE MISTRETTA  
Title: Rector

Il RETTORE  
(Pasquale Mistretta)  
*buvorutti*  
CAGLIARI, 01 APR. 2009



**Centre National Del La Recherche  
Scientifique**

By: \_\_\_\_\_ **Directeur de la Politique Industrielle**

Name: \_\_\_\_\_

Title: \_\_\_\_\_

**Marc V. LEDOUX**



L'Université Montpellier II



By: \_\_\_\_\_  
Name: Mme Danièle HéRIN  
Title: Présidente

A handwritten signature in black ink, which appears to be "Danièle HéRIN", written over the typed name "Mme Danièle HéRIN". The signature is fluid and cursive, with a large, expressive flourish at the end.

**Attachment A**  
**Jointly Owned Patents**

(See attached.)

## Attachment A for Patent Assignment Agreement

Jones Day C.A.M.	Docket No.	Identif. Ref. No.	Type Country	Inventor	Serial No.	Filed	Title
<b>IDX 1017 Patent Family</b>							
417451-988090/6	11874-016-988	1017 US PROV	PROV	Gosdin, G. Sommadossi, J.-P. Moses, A. Peters, C. Benzatti-Pied, S. Dabholkar, D. LaCella, P.	60/392,351	6/28/02	2' and 3' Nucleoside Products for Treating Hepatitis C Virus
417451-990016	11874-016-999	1017 US	CON of CON 1	11874-015-888 11874-016-888 11874-016-888	10/09/298	6/27/03	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990047	11874-017-999	1017 US	CON of CON 1	11874-016-999	11/005,471	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990048	11874-018-999	1017 US	CON of CON 2	11874-016-999 11874-016-999	11/005,442	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990049	11874-019-999	1017 US	CON of CON 3	11874-016-999 11874-016-999	11/005,466	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990050	11874-020-999	1017 US	CON of CON 4	11874-016-999 11874-016-999	11/005,440	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990051	11874-021-999	1017 US	CON of CON 5	11874-016-999 11874-016-999	11/005,443	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990052	11874-022-999	1017 US	CON of CON 6	11874-016-999 11874-016-999	11/005,446	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-990053	11874-023-999	1017 US	CON of CON 7	11874-016-999 11874-016-999	11/005,472	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections

1A-993113-1  
3/4/2009

Jones Day C.A.M.	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-000054	11874-054-099	1017 US CON & 11874-016-999	CN of CON &	Gossein, G. La Colla, A. Sommadossi, J.-P.	11005-444	12/6/04	2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-001016	11874-016-001	1017 CA	Canada	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	2,490,290	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-007016	11874-016-007	1017 AU	Australia	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	2003263412	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-008016	11874-016-008	1017 NZ	New Zealand	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	53759	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-009016	11874-016-009	1017 MX	Mexico	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	PAD20040 12779	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-010016	11874-016-010	1017 CL	Chile	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	1336-2003	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-011016	11874-016-011	1017 PE	Peru	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	666-2003	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-012016	11874-016-012	1017 JP	Japan	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	2004- 517162	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-013016	11874-016-015	1017 NO	Norway	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	20050466	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
417451-014016	11874-016-019	1017 RU	Russian Fed.	Sommadossi, J.-P. La Colla, P. Storer, R. Gossein, G.	2005102096	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections

1A12953113v1  
3/4/2009

Jones Day C.A.M	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-0220/16	11874-016-023	1017 HK	Hong Kong	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	051668126.0	8/9/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0250/16	11874-016-025	1017 VE	Venezuela	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	1106-2003	6/20/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0360/16	11874-016-036	1017 AR	Argentina	Sauer, R. Gossein, G. Inchausti, J.-L. Sommadossi, J.-P. Moussat, A.	P050102365	6/20/03	'2 and '3 Nucleoside Products for Treating Flaviviridae Infections
417451-0370/16	11874-016-037	1017 BR	Brazil	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	P051227119	6/27/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0390/16	11874-016-039	1017 PY	Paraguay	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	15964/2003	6/27/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0400/16	11874-016-040	1017 UY	Uruguay	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	271776	6/20/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0410/16	11874-016-041	1017 BO	Bolivia	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	SP-151-03 (SP-23015)	6/27/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0550/16	11874-016-055	1017 SG	Singapore	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	200407794- 7	6/27/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0560/16	11874-016-056	1017 IN	India	Sommadossi, J.-P. LaColla, P. Sauer, R. Gossein, G.	3410RELNP 2005	6/27/03	'1, '2 and '3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections

1.01-293113v1  
3/4/2009

<u>Jones Day</u>	<u>Docket No.</u>	<u>Idepix Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-0760/6	11874-016-076	1017 ID	Indonesia	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	WO2006000 216	6/27/06	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-0780/6	11874-016-073	1017 EG	Egypt	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	6/17/03	6/28/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1060/6	11874-016-06	1017 MA	Morocco	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	2/6/02	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1170/6	11874-016-117	1017 PH	Philippines	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	1-2005- 500/175	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1310/6	11874-016-131	1017 TH	Thailand	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	0834/123	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1460/6	11874-016-146	1017 CN	China	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	03/2006/0 0	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1470/6	11874-016-147	1017 ZA	South Africa	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	2004/11/269	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1500/6	11874-016-150	1017 PL	Poland	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	P/27492	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-1540/6	11874-016-154	1017 YU	Yugoslavia (former)	Somnabossi, J.-P. LaColla, P. Surer, R. Gesslein, G.	P-1141/04	6/27/03	'1, '2 and '3' Modified Nucleotide Derivatives for Treating Flavivirus Infections

Jones Day CAM	Docket No.	Identix Ref. No.	Type Related/Country	Inventor	Serial No.	Filed	Title
417451-150/016	11874-016-138	1017 IL	Israel	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	165891	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-170/016	11874-016-178	1017 PK	Pakistan	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	574/2003	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-180/016	11874-016-185	1017 TW	Taiwan	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	92117542	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-187/016	11874-016-187	1017 KK	South Korea	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	10/2004-702/1337	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-189/016	11874-016-189	1017 VN	Vietnam	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	17/0065-00169	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-240/016	11874-016-214	1017 OA	OAPI	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	2000000341	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-277/016	11874-016-227	1017 EP	EPO	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	03761749.5	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-220/016	11874-016-228	1017 NO	FCT	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	PC/IB/2003/000901	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections
417451-241/016	11874-016-241	1017 MY	Malaysia	Sommadossi, J.-P. LaColla, P. Storer, R. Gossein, G.	700023235	6/27/03	1', 2' and 3' Modified Nucleotide Derivatives for Treating Flavivirus Infections

LA129511111  
3/4/2009

Jones Day CAM	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-265016	11874-016-262	1017 US APIO	Sommadossi, J.-P.; LaColla, P.; Soveri, R.; Gossetin, G.	Affp050003 211	6/27/03		1', 2', and 3' Modified Nucleotide Derivatives for Treating Flaviviridae Infections
<b>IDX 1018 Patent Family</b>							
417451-388035	11874-055-888	1018 US PROV	Soveri, R.; Gossetin, G.; Sommadossi, J.-P.; Nessoz, A.; LaColla, P.	6/6/92-239	6/28/02		Modified 2' and 3' Nucleotide Products for Treating Hepatitis C Virus
417451-399055	11874-055-999	1018 US	11874-015-888 11874-055-888 11874-055-999	Soveri, R.; Gossetin, G.; LaColla, P.; Sommadossi, J.-P.	10/6/88-907	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399056	11874-056-999	1018 US CON of CON 1	11874-055-999	LaColla, P.; Soveri, R.; Gossetin, G.; Sommadossi, J.-P.	11/005,445	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399057	11874-057-999	1018 US CON 2	11874-055-999	LaColla, P.; Soveri, R.; Gossetin, G.; Sommadossi, J.-P.	11/005,473	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399058	11874-058-999	1018 US CON 3	11874-055-999	Soveri, R.; Gossetin, G.; LaColla, P.; Sommadossi, J.-P.	11/005,468	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399059	11874-059-999	1018 US CON 4	11874-055-999	LaColla, P.; Soveri, R.; Gossetin, G.; Sommadossi, J.-P.	11/005,467	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399060	11874-060-999	1018 US CON 5	11874-055-999	LaColla, P.; Soveri, R.; Gossetin, G.; Sommadossi, J.-P.	11/005,470	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-399061	11874-061-999	1018 US CON 6	11874-055-999	Soveri, R.; Gossetin, G.; LaColla, P.; Sommadossi, J.-P.	11/005,447	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections

141295111  
3/4/2009

<u>Jones Day C.A.M</u>	<u>Docket No.</u>	<u>Identix Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-999062	11874-062-999	1018 US CON 7	COR of 11874-055-999	Soyer, R. Gosselin, G. LaColla, P. Semmatoosi, J.-P.	11/005,441	12/26/04	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-999063	11874-063-999	1018 US CON 8	COR of 11874-055-999	LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P.	11/005,469	12/26/04	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-999190	11874-190-999	1018 US DIV	EPO of 11874- 055-999	LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P.	12/131,868	6/2/08	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-001055	11874-035-001	1018 CA Canada		LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P.	2,490,191	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-001055	11874-035-007	1018 AU	Australia	Soyer, R. Gosselin, G. LaColla, P. Semmatoosi, J.-P.	2000/247084	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-008055	11874-055-004	1018 NZ	New Zealand	LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P.	537/663	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-008055	11874-055-009	1018 MX	Mexico	LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P.	P45/2004/0 12/09	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-010055	11874-055-010	1018 CL	Chile	Soyer, R. Gosselin, G. LaColla, P. Semmatoosi, J.-P.	1337-2003	6/2/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-011055	11874-035-011	1018 PE	Peru	LaColla, P. Soyer, R. Gosselin, G. Semmatoosi, J.-P	065/94/2003	6/2/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections

LAI-293113v1  
3/4/2009

Jones Day CAM	Docket No.	Identis Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-012055	11874-055-012	1018 JP	Japan	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	2004- 517158	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-012055	11874-055-015	1018 NO	Norway	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	20050465	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-02055	11874-055-019	1018 RU	Russian Fed.	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	2005102013	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-023055	11874-055-023	1018 HK	Hong Kong	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	051669742	8/1/05	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-025055	11874-055-025	1018 VE	Venezuela	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	1101-2003	6/3/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-036055	11874-055-036	1018 AR	Argentina	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	PI00102366	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-037055	11874-055-037	1018 BR	Brazil	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	PI01122867	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-039055	11874-055-039	1018 PY	Paraguay	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	156917/2003	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-040055	11874-055-040	1018 UY	Uruguay	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	213135	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

1A-2951131  
3/4/2009

Jones Day C.A.M	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-041055	11874-055-041	1018 BO	Bolivia	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	SP-159-03	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-055055	11874-055-055	1018 SG	Singapore	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	200407747-5	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-056055	11874-055-056	1018 IN	India	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	343/DELNP /2005	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-076055	11874-055-076	1018 ID	Indonesia	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	W02005050 215	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-078055	11874-055-078	1018 EG	Egypt	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	171/2004	4/18/2004	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-106055	11874-055-106	1018 MA	Morocco	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	280/69	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-170055	11874-055-117	1018 PH	Philippines	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	12005- 500/173	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-131055	11874-055-131	1018 TH	Thailand	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	083/24	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
417451-146055	11874-055-146	1018 CN	China	Sover, R. Gosselin, G. LaColla, P. Sommaroseti, J.-P.	038/20301/7	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections

11/29/2011 (3)  
3/4/2009

Jones Day C.A.M.	Docket No.	Identix Ref. No.	Type Related/ Country	Investor	Serial No.	Filed	Title
417451-147055	11874-055-147	1018 ZA	South Africa	LaColla, P. Sauer, R. Gosolin, G. Semnakoss, J.-P.	200410249	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-150055	11874-055-150	1018 PL	Poland	LaColla, P. Sauer, R. Gosolin, G. Semnakoss, J.-P.	F-1174831	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-154055	11874-055-154	1018 YU (former)	Yugoslavia	Sauer, R. Gosolin, G. LaColla, P. Semnakoss, J.-P.	P-114004	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-158055	11874-055-158	1018 IL	Israel	Sauer, R. Gosolin, G. LaColla, P. Semnakoss, J.-P.	165893	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-178055	11874-055-178	1018 PK	Pakistan	LaColla, P. Sauer, R. Gosolin, G. Semnakoss, J.-P.	5802003	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-185055	11874-055-185	1018 TW	Taiwan	Sauer, R. Gosolin, G. LaColla, P. Semnakoss, J.-P.	92117546	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-187055	11874-055-187	1018 KR	South Korea	LaColla, P. Sauer, R. Gosolin, G. Semnakoss, J.-P.	102004- 7021286	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-189055	11874-055-189	1018 VN	Vietnam	LaColla, P. Sauer, R. Gosolin, G. Semnakoss, J.-P.	I-2005- 00107	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-214055	11874-055-214	1018 OA	OAPI	Sauer, R. Gosolin, G. LaColla, P. Semnakoss, J.-P.	I200400344	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections

1A1-2951131  
3/4/2009

Jones Day C.A.M.	Docket No.	Identif. Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title	
417451-222055	11874-055-227	1018 EP	EPO	La Colla, P. Sauer, R. Goscelin, G. Sommaleskoski, J.-P.	03761744-6	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections	
417451-223055	11874-055-228	1018 WO	PCT	La Colla, P. Sauer, R. Goscelin, G. Sommaleskoski, J.-P.	PCT/IB2003 003246	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections	
417451-241055	11874-055-241	1018 MY	Malaysia	Sauer, R. Goscelin, G. La Colla, P. Sommaleskoski, J.-P.	P100032435	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections	
417451-262055	11874-055-262	1018 AP	ARIPO	La Colla, P. Sauer, R. Goscelin, G. Sommaleskoski, J.-P.	AF/P2005/040	6/27/03	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections	
417451-146144	11874-144-146	1018 CN (DLY)	China	La Colla, P. Sauer, R. Goscelin, G. Sommaleskoski, J.-P.	2007101993 010	12/20/07	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections	
<b>IDX 1031 Patent Family</b>								
417451-099025	11874-026-999	1031 US	CON 1	11874-016-888 11874-130-888	La Colla, P. Goscelin, G.	10/607,909	6/27/03	<sup>2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of</sup> Flaviviridae Infections
417451-099086	11874-086-999	1031 US	CON 1	11874-026-999	La Colla, P. Goscelin, G.	11/516,928	9/6/06	<sup>2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of</sup> Flaviviridae Infections
417451-001026	11874-026-001	1031 CA	Canada		La Colla, P.	2,489,552	6/27/03	<sup>2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of</sup> Flaviviridae Infections
417451-007026	11874-026-007	1031 AU	Australia		La Colla, P. Goscelin, G.	20052487448	6/27/03	<sup>2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of</sup> Flaviviridae Infections
417451-008026	11874-026-008	1031 NZ	New Zealand		La Colla, P. Goscelin, G.	537662	6/27/03	<sup>2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of</sup> Flaviviridae Infections

1A1-20531111v  
3/4/2009

Jones Day C.A.M	Docket No.	Identis Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-009026	11874-026-069	1031 MX	Mexico	Somnadevi, J.-P. La Colla, P. Goselin, G.	PA/S/2004/0 12802	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-01026	11874-026-010	1031 CL	Chile	Somnadevi, J.-P. La Colla, P. Goselin, G.	1338-2003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-01126	11874-026-011	1031 PE	Peru	Somnadevi, J.-P. La Colla, P. Goselin, G.	000661- 2003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-01226	11874-026-012	1031 JP	Japan	Somnadevi, J.-P. La Colla, P. Goselin, G.	2004- 518041	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-01526	11874-026-015	1031 NO	Norway	Somnadevi, J.-P. La Colla, P. Goselin, G.	2005/090	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-01926	11874-026-019	1031 RU	Russian Fed.	Somnadevi, J.-P. La Colla, P. Goselin, G.	2005/102860	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-02326	11874-026-023	1031 HK	Hong Kong	Somnadevi, J.-P. La Colla, P. Goselin, G.	05106114.3	7/19/05	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-02526	11874-026-025	1031 VE	Venezuela	Somnadevi, J.-P. La Colla, P. Goselin, G.	1099-2003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-03626	11874-026-036	1031 AR	Argentina	Somnadevi, J.-P. La Colla, P. Goselin, G.	P040/02363	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-03726	11874-026-037	1031 BR	Brazil	Somnadevi, J.-P. La Colla, P. Goselin, G.	PR01/2278-5	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-03926	11874-026-039	1031 PY	Paraguay	Somnadevi, J.-P. La Colla, P. Goselin, G.	1596/2003	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections
417451-04026	11874-026-040	1031UY	Uruguay	Somnadevi, J.-P. La Colla, P. Goselin, G.	27174	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infections

LA-3931131  
3/4/2009

<u>Issue Date</u> <u>CAN</u>	<u>Docket No.</u>	<u>Identix Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
4-17451-041/026	11874-026-641	1031 BO	Bolivia	Sammadossi, J.-P. La Colla, P. Gossein, G.	SP-230149	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-055/026	11874-026-635	1031 SG	Singapore	Sammadossi, J.-P. La Colla, P. Gossein, G.	9	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-056/026	11874-026-636	1031 IN	India	Sammadossi, J.-P. La Colla, P. Gossein, G.	34-DELNP 2/2005	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-076/026	11874-026-076	1031 ID	Indonesia	Sammadossi, J.-P. La Colla, P. Gossein, G.	W02003050 2/14	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-078/026	11874-026-078	1031 EG	Egypt	Sammadossi, J.-P. La Colla, P. Gossein, G.	6/16/2003	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-106/026	11874-026-106	1031 MA	Morocco	Sammadossi, J.-P. La Colla, P. Gossein, G.	28/20	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-117/026	11874-026-117	1031 PH	Philippines	Sammadossi, J.-P. La Colla, P. Gossein, G.	1-2005- 500172	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-131/026	11874-026-131	1031 TH	Thailand	Sammadossi, J.-P. La Colla, P. Gossein, G.	03/24/22	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-146/026	11874-026-146	1031 CN	China	Sammadossi, J.-P. La Colla, P. Gossein, G.	01820701X	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-147/026	11874-026-147	1031 ZA	South Africa	Sammadossi, J.-P. La Colla, P. Gossein, G.	2004/02/29	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-150/026	11874-026-150	1031 PL	Poland	Sammadossi, J.-P. La Colla, P. Gossein, G.	P-374781	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
4-17451-154/026	11874-026-154	1031 YU	Yugoslavia (former)	Sammadossi, J.-P. La Colla, P. Gossein, G.	Y-139004	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections

LA12951131  
342/069

Jones Day C.A.M.	Docket No. Ref. No.	Identis Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-158026	11874-026-138	1031 IL	Israel	Sommadoso, J.-P. La Colla, P. Gossein, G.	165157	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-178026	11874-026-178	1031 PK	Pakistan	Sommadoso, J.-P. La Colla, P. Gossein, G.	5790003	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-183026	11874-026-185	1031 TW	Taiwan	Sommadoso, J.-P. La Colla, P. Gossein, G.	92117544	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-187026	11874-026-187	1031 KR	South Korea	Sommadoso, J.-P. La Colla, P. Gossein, G.	10-2004-7010703	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-189026	11874-026-189	1031 VN	Vietnam	Sommadoso, J.-P. La Colla, P. Gossein, G.	1-2005-00106	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-2-4026	11874-026-214	1031 OA	OAPI	Sommadoso, J.-P. La Colla, P. Gossein, G.	2006/00043	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-229026	11874-026-227	1031 EP	EPO	Sommadoso, J.-P. La Colla, P. Gossein, G.	03762183.6	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-228026	11874-026-228	1031 WO	PCT	Sommadoso, J.-P. La Colla, P. Gossein, G.	PCT/AU2000/0031	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-241026	11874-026-241	1031 MY	Malaysia	Sommadoso, J.-P. La Colla, P. Gossein, G.	P2002434	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-252026	11874-026-262	1031 AP	ARIPD	Sommadoso, J.-P. La Colla, P. Gossein, G.	APR/00050	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-068086	11874-086-008	1031 NZ (DVI)	New Zealand	Sommadoso, J.-P. La Colla, P. Gossein, G.	556268	7/2/07	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections
417451-055086	11874-086-055	1031 SG (DVI)	Singapore	Sommadoso, J.-P. La Colla, P. Gossein, G.	200700448-9	1/26/07	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinyl Cytidine for Treatment of Flaviviridae Infections

1A-3931131  
3/4/2009

Jones Day C.A.M	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-056086	11874-086-456	1031 IN (DIV)	India	Somnathoski, J.-P. La Cotta, P. Gosdin, G.	88606DELN PZ/2007	11/15/07	2-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infection
417451-146086	11874-086-146	1031 CN (DIV)	China	Somnathoski, J.-P. La Cotta, P. Gosdin, G.	2006/01099 SO/7	12/10/07	2-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infection
417451-147086	11874-086-147	1031 JA (DIV)	South Africa	Somnathoski, J.-P. La Cotta, P. Gosdin, G.	2006/07218	8/29/06	2-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infection
417451-178086	11874-086-178	1031 PK (DIV)	Pakistan	Somnathoski, J.-P. La Cotta, P. Gosdin, G.	542/2007	1/20/07	2-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviridae Infection
<b>IDX 1040 Parent Family</b>							
417451-488077	11874-077-383	1040 US PROV		Gosdin, G. Seitz, F. La Cotta, P. Sauer, R. Dishman, D. Levy, F.	6/0/382,182	6/23/04	5-AzA-7-Desazapentapeptides for Treating Flaviviridae
417451-399077	11874-077-399	1040 US	11874-077-383	Gosdin, G. Seitz, F. La Cotta, P. Sauer, R. Dishman, D. Levy, F.	11/16,498	6/21/05	5-AzA-7-Desazapentapeptides Derivatives for Treating Flaviviridae
417451-491077	11874-077-201	1040 CA	Canada	Gosdin, G. Seitz, F. La Cotta, P. Sauer, R. Dishman, D. Levy, F.	2,571,675	6/21/05	5-AzA-7-Desazapentapeptides Derivatives for Treating Flaviviridae
417451-492077	11874-077-202	1040 AU	Australia	Gosdin, G. Seitz, F. La Cotta, P. Sauer, R. Dishman, D. Levy, F.	2006226693	6/23/05	5-AzA-7-Desazapentapeptides Derivatives for Treating Flaviviridae

1A1-2931131  
3/4/2009

Jones Day CAM	Docket No.	Ideas Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-00077	11874-077-008	1040 NZ	New Zealand	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	552612 15065	6/23/05 6/23/06	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-00077	11874-077-200	1040 MX	Mexico	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	PAT/A/2006/0 517530	6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-012077	11874-077-012	1040 JP	Japan	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	20071 20071	6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-015077	11874-077-015	1040 NO	Norway	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	2007070340	6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-019077	11874-077-019	1040 RU	Russian Fed.	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	200702381 200712360	6/23/05 6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-037077	11874-077-037	1040 BR	Brazil	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	FIB/12360-7	6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae
417451-055077	11874-077-055	1040 SG	Singapore	Gosselin, G. Seitz, F. LaCola, P. Sauer, R. Dukhan, D. Letoy, F.	2006080949- 4	6/23/05	5-Aza-7-Desazupurine Derivatives for Treating Flaviviridae

LAI:293113v1  
3/4/2009

Jones Day CAM	Docket No.	Identis Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-056077	11874-077-056	1040 IN		Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	47010ELNP 2/2007	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-070077	11874-077-078	1040 EG	EPO	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	PCT/IT2004/020 06	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-146077	11874-077-146	1040 CN	China	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	2005100257 94.6	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-156077	11874-077-154	1040 YU	Vietnam (former)	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	P-200606044	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-158077	11874-077-158	1040 IL	Israel	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	I-02000	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-187077	11874-077-187	1040 KR	South Korea	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	10-2007-7001047	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
417451-227077	11874-077-227	1040 EP	EPO	Gossein, G. Sechi, F. LaColla, P. Sover, R. Dukhan, D. Leroy, F.	05778001.7	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae

1A1-2931131  
3/4/2009

Judge Day C.A.M	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
4/17/451-238077	11874-977-238	1140 WO	PCT	Goschkin, G. Sechi, F. La Cilia, P. Sover, R. Dakian, D. Latoro, F.	PT/TIB2005 N002768	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae
4/17/451-235077	11874-977-255	1140 USA	Ukraine	Goschkin, G. Sechi, F. La Cilia, P. Sover, R. Dakian, D. Latoro, F.	200700649	6/23/05	5-Aza-7-Desazepine Derivatives for Treating Flaviviridae

1A1-293113x1  
3/4/2009